Table 1: Overall survival and values of Docetaxel and Ramucirumab in 2nd-line.
| Nivo in 2nd-line | OS gains in days/Grade (OS/gr) & HR | $4-week Costs | $C/LYG |
|---|---|---|---|
| ♣Generic docetaxel (Doc) 75 mg/m2 vs. supportive care [1] | 87/C HR not reported P = 0.01 | $500 | $26,897 |
| ♣Ramucirumab (Ramu) + Doc vs. Doc, squamous and non-squamous, (REVEL) [16] | 42/D HR 0.86 P = 0.0235 | $9,333 | $1,039,963 |
The C/LYG = year-cost/OS gain x 360 days. ♣Doc and Ramu demonstrated AEs gr > 20% and had black box warnings. The C/LYG of Doc and Ramu were not calculated relative to $100,000.